Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs
- Pålhagen, Sven E.
- Sydow, Olof
- Johansson, Anders
- Nyholm, Dag
- Holmberg, Bjorn
- Widner, Hakan
- Dizdar, Nil
- Linder, Jan
- Hauge, Tove
- Jansson, Rasmus
- Bergmann, Lars
- Kjellander, Susanna
- Marshall, Thomas S.
DOIAbstract
AbstractBackgroundContinuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage motor and non-motor complications in advanced Parkinson’s disease (PD). Healthcare costs, quality of life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG.MethodsThe seventy-seven patients enrolled in this prospective, open-label, 3-year study in routine medical care were LCIG-naïve (N = 37), or had previous LCIG treatment for <2 (N = 22), or ≥2 (N = 18) years. Healthcare costs were collected monthly. PD symptoms and QoL were assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS), 39-item Parkinson’s Disease Questionnaire (PDQ-39), and EuroQoL 5-Dimension Visual Analog Scale (EQ-5D VAS)...
Add to ORKG